Palvella Therapeutics, Inc.
PVLA
$120.57
-$5.22-4.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.77M | -12.71M | -11.35M | -9.47M | -8.19M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.36M | 3.98M | 3.62M | 2.91M | 2.38M |
| Change in Net Operating Assets | -455.00K | 3.80M | -153.00K | 1.13M | -967.00K |
| Cash from Operations | -10.86M | -4.93M | -7.88M | -5.43M | -6.77M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.44M | -- | -- | -- | -- |
| Cash from Investing | -55.44M | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 230.96M | 105.00K | 242.00K | 349.00K | 67.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -16.23M | -154.00K | 0.00 | 0.00 | -1.27M |
| Cash from Financing | 214.73M | -49.00K | 242.00K | 349.00K | -1.20M |
| Foreign Exchange rate Adjustments | -15.00K | -610.00K | 770.00K | -108.00K | -6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 148.41M | -5.59M | -6.87M | -5.19M | -7.98M |